ArticleNeurology2022
Association of Plasma Biomarker Levels With Their CSF Concentration and the Number and Severity of Concussions in Professional Athletes.
Open access · greenAbstract read
In one paragraph
Article in Neurology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
4.4field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.
- Diagnostic and prognostic role of serum/plasma and CSF amyloid beta peptide levels in traumatic brain injury: a systematic review and meta-analysis.Neurosurgical review · 2025Pooled it
- Article
- Neuroinflammatory mechanisms may help identify candidate biomarkers in chronic traumatic encephalopathy (CTE).Free neuropathology · 2025Review
- Plasma phosphorylated tau-217 correlates with brain atrophy, cognition, and cerebrospinal fluid biomarkers in a cognitively healthy community cohort.Brain communications · 2025Article
- APOE4 and age affect the brain entorhinal cortex structure and blood arachidonic acid and docosahexaenoic acid levels after mild TBI.Scientific reports · 2024Article
- Examination of plasma biomarkers of amyloid, tau, neurodegeneration, and neuroinflammation in former elite American football players.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- gp120-derived amyloidogenic peptides form amyloid fibrils that increase HIV-1 infectivity.Cellular & molecular immunology · 2024Article
- Blood-Based Biomarkers in the Diagnosis of Chronic Traumatic Encephalopathy: Research to Date and Future Directions.International journal of molecular sciences · 2023Review
- Alzheimer's pathology is associated with altered cognition, brain volume, and plasma biomarker patterns in traumatic encephalopathy syndrome.Alzheimer's research & therapy · 2023Article
- Longitudinal Associations Between Blood Biomarkers and White Matter MRI in Sport-Related Concussion: A Study of the NCAA-DoD CARE Consortium.Neurology · 2023Article
- A year in review: brain barriers and brain fluids research in 2022.Fluids and barriers of the CNS · 2023Article
- Early Diagnosis of Alzheimer's Disease: Moving Toward a Blood-Based Biomarkers Era.Clinical interventions in aging · 2023Article
- Updated Review of Neurologic Concussion Biomarkers for Time-sensitive Point-of-care Testing.Journal of emergencies, trauma, and shockReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Pashtun ShahimFrom the Institute of Neuroscience and Physiology (P.S., H.Z., J.S., N.J.A., M.S., K.B.), Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at University of Gothenburg; Clinical Neurochemistry Laboratory (P.S., H.Z., J.S., N.J.A., K.B.), Sahlgrenska University Hospital, Mölndal, Sweden; Rehabilitation Medicine Department (P.S.), National Institutes of Health Clinical Center, Bethesda, MD; Department of Neurodegenerative Disease (H.Z.), UCL Institute of Neurology, Queen Square, United Kingdom; UK Dementia Research Institute (H.Z.), London; Wallenberg Centre for Molecular and Translational Medicine (N.J.A., M.S.), University of Gothenburg, Sweden; King's College London (N.J.A.), Institute of Psychiatry, Psychology and Neuroscience, Maurice Wohl Institute Clinical Neuroscience Institute; NIHR Biomedical Research Centre for Mental Health and Biomedical Research Unit for Dementia at South London and Maudsley NHS Foundation (N.J.A.), United Kingdom; Clinical Trials Unit (G.N.), National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD; Division of Health (Y.T.), Medicine and Rehabilitation, Department of Health Science, Luleå University of Technology, Sweden; and Department of Neurology (R.D.-A.), University of Pennsylvania Perelman School of Medicine, Philadelphia. Pashtun.shahim@gmail.com.
Henrik ZetterbergFrom the Institute of Neuroscience and Physiology (P.S., H.Z., J.S., N.J.A., M.S., K.B.), Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at University of Gothenburg; Clinical Neurochemistry Laboratory (P.S., H.Z., J.S., N.J.A., K.B.), Sahlgrenska University Hospital, Mölndal, Sweden; Rehabilitation Medicine Department (P.S.), National Institutes of Health Clinical Center, Bethesda, MD; Department of Neurodegenerative Disease (H.Z.), UCL Institute of Neurology, Queen Square, United Kingdom; UK Dementia Research Institute (H.Z.), London; Wallenberg Centre for Molecular and Translational Medicine (N.J.A., M.S.), University of Gothenburg, Sweden; King's College London (N.J.A.), Institute of Psychiatry, Psychology and Neuroscience, Maurice Wohl Institute Clinical Neuroscience Institute; NIHR Biomedical Research Centre for Mental Health and Biomedical Research Unit for Dementia at South London and Maudsley NHS Foundation (N.J.A.), United Kingdom; Clinical Trials Unit (G.N.), National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD; Division of Health (Y.T.), Medicine and Rehabilitation, Department of Health Science, Luleå University of Technology, Sweden; and Department of Neurology (R.D.-A.), University of Pennsylvania Perelman School of Medicine, Philadelphia.ORCID 0000-0002-4671-6763
Joel SimrénFrom the Institute of Neuroscience and Physiology (P.S., H.Z., J.S., N.J.A., M.S., K.B.), Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at University of Gothenburg; Clinical Neurochemistry Laboratory (P.S., H.Z., J.S., N.J.A., K.B.), Sahlgrenska University Hospital, Mölndal, Sweden; Rehabilitation Medicine Department (P.S.), National Institutes of Health Clinical Center, Bethesda, MD; Department of Neurodegenerative Disease (H.Z.), UCL Institute of Neurology, Queen Square, United Kingdom; UK Dementia Research Institute (H.Z.), London; Wallenberg Centre for Molecular and Translational Medicine (N.J.A., M.S.), University of Gothenburg, Sweden; King's College London (N.J.A.), Institute of Psychiatry, Psychology and Neuroscience, Maurice Wohl Institute Clinical Neuroscience Institute; NIHR Biomedical Research Centre for Mental Health and Biomedical Research Unit for Dementia at South London and Maudsley NHS Foundation (N.J.A.), United Kingdom; Clinical Trials Unit (G.N.), National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD; Division of Health (Y.T.), Medicine and Rehabilitation, Department of Health Science, Luleå University of Technology, Sweden; and Department of Neurology (R.D.-A.), University of Pennsylvania Perelman School of Medicine, Philadelphia.
Nicholas J AshtonFrom the Institute of Neuroscience and Physiology (P.S., H.Z., J.S., N.J.A., M.S., K.B.), Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at University of Gothenburg; Clinical Neurochemistry Laboratory (P.S., H.Z., J.S., N.J.A., K.B.), Sahlgrenska University Hospital, Mölndal, Sweden; Rehabilitation Medicine Department (P.S.), National Institutes of Health Clinical Center, Bethesda, MD; Department of Neurodegenerative Disease (H.Z.), UCL Institute of Neurology, Queen Square, United Kingdom; UK Dementia Research Institute (H.Z.), London; Wallenberg Centre for Molecular and Translational Medicine (N.J.A., M.S.), University of Gothenburg, Sweden; King's College London (N.J.A.), Institute of Psychiatry, Psychology and Neuroscience, Maurice Wohl Institute Clinical Neuroscience Institute; NIHR Biomedical Research Centre for Mental Health and Biomedical Research Unit for Dementia at South London and Maudsley NHS Foundation (N.J.A.), United Kingdom; Clinical Trials Unit (G.N.), National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD; Division of Health (Y.T.), Medicine and Rehabilitation, Department of Health Science, Luleå University of Technology, Sweden; and Department of Neurology (R.D.-A.), University of Pennsylvania Perelman School of Medicine, Philadelphia.ORCID 0000-0002-3579-8804
Gina NoratoFrom the Institute of Neuroscience and Physiology (P.S., H.Z., J.S., N.J.A., M.S., K.B.), Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at University of Gothenburg; Clinical Neurochemistry Laboratory (P.S., H.Z., J.S., N.J.A., K.B.), Sahlgrenska University Hospital, Mölndal, Sweden; Rehabilitation Medicine Department (P.S.), National Institutes of Health Clinical Center, Bethesda, MD; Department of Neurodegenerative Disease (H.Z.), UCL Institute of Neurology, Queen Square, United Kingdom; UK Dementia Research Institute (H.Z.), London; Wallenberg Centre for Molecular and Translational Medicine (N.J.A., M.S.), University of Gothenburg, Sweden; King's College London (N.J.A.), Institute of Psychiatry, Psychology and Neuroscience, Maurice Wohl Institute Clinical Neuroscience Institute; NIHR Biomedical Research Centre for Mental Health and Biomedical Research Unit for Dementia at South London and Maudsley NHS Foundation (N.J.A.), United Kingdom; Clinical Trials Unit (G.N.), National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD; Division of Health (Y.T.), Medicine and Rehabilitation, Department of Health Science, Luleå University of Technology, Sweden; and Department of Neurology (R.D.-A.), University of Pennsylvania Perelman School of Medicine, Philadelphia.
Michael SchöllFrom the Institute of Neuroscience and Physiology (P.S., H.Z., J.S., N.J.A., M.S., K.B.), Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at University of Gothenburg; Clinical Neurochemistry Laboratory (P.S., H.Z., J.S., N.J.A., K.B.), Sahlgrenska University Hospital, Mölndal, Sweden; Rehabilitation Medicine Department (P.S.), National Institutes of Health Clinical Center, Bethesda, MD; Department of Neurodegenerative Disease (H.Z.), UCL Institute of Neurology, Queen Square, United Kingdom; UK Dementia Research Institute (H.Z.), London; Wallenberg Centre for Molecular and Translational Medicine (N.J.A., M.S.), University of Gothenburg, Sweden; King's College London (N.J.A.), Institute of Psychiatry, Psychology and Neuroscience, Maurice Wohl Institute Clinical Neuroscience Institute; NIHR Biomedical Research Centre for Mental Health and Biomedical Research Unit for Dementia at South London and Maudsley NHS Foundation (N.J.A.), United Kingdom; Clinical Trials Unit (G.N.), National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD; Division of Health (Y.T.), Medicine and Rehabilitation, Department of Health Science, Luleå University of Technology, Sweden; and Department of Neurology (R.D.-A.), University of Pennsylvania Perelman School of Medicine, Philadelphia.ORCID 0000-0001-7800-1781
Yelverton TegnerFrom the Institute of Neuroscience and Physiology (P.S., H.Z., J.S., N.J.A., M.S., K.B.), Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at University of Gothenburg; Clinical Neurochemistry Laboratory (P.S., H.Z., J.S., N.J.A., K.B.), Sahlgrenska University Hospital, Mölndal, Sweden; Rehabilitation Medicine Department (P.S.), National Institutes of Health Clinical Center, Bethesda, MD; Department of Neurodegenerative Disease (H.Z.), UCL Institute of Neurology, Queen Square, United Kingdom; UK Dementia Research Institute (H.Z.), London; Wallenberg Centre for Molecular and Translational Medicine (N.J.A., M.S.), University of Gothenburg, Sweden; King's College London (N.J.A.), Institute of Psychiatry, Psychology and Neuroscience, Maurice Wohl Institute Clinical Neuroscience Institute; NIHR Biomedical Research Centre for Mental Health and Biomedical Research Unit for Dementia at South London and Maudsley NHS Foundation (N.J.A.), United Kingdom; Clinical Trials Unit (G.N.), National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD; Division of Health (Y.T.), Medicine and Rehabilitation, Department of Health Science, Luleå University of Technology, Sweden; and Department of Neurology (R.D.-A.), University of Pennsylvania Perelman School of Medicine, Philadelphia.
Ramon Diaz-ArrastiaFrom the Institute of Neuroscience and Physiology (P.S., H.Z., J.S., N.J.A., M.S., K.B.), Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at University of Gothenburg; Clinical Neurochemistry Laboratory (P.S., H.Z., J.S., N.J.A., K.B.), Sahlgrenska University Hospital, Mölndal, Sweden; Rehabilitation Medicine Department (P.S.), National Institutes of Health Clinical Center, Bethesda, MD; Department of Neurodegenerative Disease (H.Z.), UCL Institute of Neurology, Queen Square, United Kingdom; UK Dementia Research Institute (H.Z.), London; Wallenberg Centre for Molecular and Translational Medicine (N.J.A., M.S.), University of Gothenburg, Sweden; King's College London (N.J.A.), Institute of Psychiatry, Psychology and Neuroscience, Maurice Wohl Institute Clinical Neuroscience Institute; NIHR Biomedical Research Centre for Mental Health and Biomedical Research Unit for Dementia at South London and Maudsley NHS Foundation (N.J.A.), United Kingdom; Clinical Trials Unit (G.N.), National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD; Division of Health (Y.T.), Medicine and Rehabilitation, Department of Health Science, Luleå University of Technology, Sweden; and Department of Neurology (R.D.-A.), University of Pennsylvania Perelman School of Medicine, Philadelphia.
Kaj BlennowFrom the Institute of Neuroscience and Physiology (P.S., H.Z., J.S., N.J.A., M.S., K.B.), Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at University of Gothenburg; Clinical Neurochemistry Laboratory (P.S., H.Z., J.S., N.J.A., K.B.), Sahlgrenska University Hospital, Mölndal, Sweden; Rehabilitation Medicine Department (P.S.), National Institutes of Health Clinical Center, Bethesda, MD; Department of Neurodegenerative Disease (H.Z.), UCL Institute of Neurology, Queen Square, United Kingdom; UK Dementia Research Institute (H.Z.), London; Wallenberg Centre for Molecular and Translational Medicine (N.J.A., M.S.), University of Gothenburg, Sweden; King's College London (N.J.A.), Institute of Psychiatry, Psychology and Neuroscience, Maurice Wohl Institute Clinical Neuroscience Institute; NIHR Biomedical Research Centre for Mental Health and Biomedical Research Unit for Dementia at South London and Maudsley NHS Foundation (N.J.A.), United Kingdom; Clinical Trials Unit (G.N.), National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD; Division of Health (Y.T.), Medicine and Rehabilitation, Department of Health Science, Luleå University of Technology, Sweden; and Department of Neurology (R.D.-A.), University of Pennsylvania Perelman School of Medicine, Philadelphia.ORCID 0000-0002-1890-4193
University of Gothenburg · SE
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesTo examine whether the brain biomarkers total-tau (T-tau), glial fibrillary acidic protein (GFAP), and β-amyloid (Aβ) isomers 40 and 42 in plasma relate to the corresponding concentrations in CSF, blood-brain barrier integrity, and duration of postconcussion syndrome (PCS) due to repetitive head impacts (RHIs) in professional athletes.
methodIn this cross-sectional study, professional athletes with persistent PCS due to RHI (median of 1.5 years after recent concussion) and uninjured controls were assessed with blood and CSF sampling. The diagnosis of PCS was based on the
resultsA total of 47 participants (28 athletes [median age 28 years, range 18-52] with persistent PCS due to RHI and 19 controls [median age, 25 years, range 21-35]) underwent paired blood and CSF sampling. T-tau, Aβ40, and Aβ42 concentrations measured in plasma did not correlate with the corresponding CSF concentrations, while there was a correlation between plasma and CSF levels of GFAP ( DISCUSSION: T-tau, GFAP, Aβ40, and Aβ42 measured in plasma do not correspond to CSF measures and may have limited utility for the evaluation of the late effects of RHI, compared with when measured in CSF. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that in professional athletes with postconcussion symptoms, plasma concentrations of T-tau, GFAP, Aβ40, and Aβ42 are not informative in the diagnosis of late effects of repetitive head injuries.
Indexed as
BiomarkersBrain ConcussionPost-Concussion SyndromeAdolescentAdultAmyloid beta-PeptidesAthletesCross-Sectional StudiesHumansMiddle AgedPeptide Fragmentstau ProteinsYoung AdultAmyloid beta-PeptidesBiomarkersPeptide Fragmentstau Proteins
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.